Medicine and Dentistry
Outpatient
39%
B-Cell Chronic Lymphocytic Leukemia
30%
Leukemia Cell
30%
Follicular Lymphoma
30%
Gemcitabine
30%
Prognostic Factor
30%
Breast Cancer
30%
Oxaliplatin
30%
Vascular Endothelium
30%
Hodgkin's Lymphoma
30%
Rituximab
30%
Melanoma
30%
Allogeneic Stem Cell Transplantation
30%
Genetic Transcription
30%
Immunoglobulin Enhancer Binding Protein
30%
Aggressive Lymphoma
30%
Alemtuzumab
30%
Drug Megadose
30%
Hyperglycemia
30%
Lymphoproliferative Disease
30%
Diabetes
30%
Diseases
21%
Antiapoptotic
18%
Cumulative Incidence
15%
Graft Versus Host Reaction
15%
Allogeneic Hematopoietic Stem Cell Transplantation
15%
Hematopoietic Stem Cell Transplantation
15%
Protein Bcl 2
12%
Endothelial Cell
12%
Maturity Onset Diabetes of the Young
11%
Overall Survival
9%
High Risk Population
9%
Stem Cell Transplant
9%
Febrile Neutropenia
9%
Neoplasm
8%
Cancer Prognosis
8%
Cancer Diagnosis
8%
Hemoglobin A1c
7%
Capillary Blood
7%
Blood Glucose
7%
B Cell
6%
In Vitro
6%
Vascularity
6%
Multigene Family
6%
Vascular Endothelial Cell
6%
DNA Binding
6%
Cell Line
6%
Protein Family
6%
Cell Survival
6%
Programmed Cell Death
6%
Immunology and Microbiology
Leukemia Cell
95%
CD49d
87%
CD38
55%
Coculture
48%
Lymph Node
34%
CD44
34%
Vascular Endothelium
30%
Immunoglobulin Enhancer Binding Protein
30%
Genetic Transcription
30%
Allogeneic Stem Cell Transplantation
30%
Alemtuzumab
30%
CXCR4
30%
B Cell
26%
Bcl-2
24%
Lymphoid Tissue
16%
Graft-Versus-Host Disease
15%
Allogeneic Hematopoietic Stem Cell Transplantation
15%
Hematopoietic Stem Cell Transplantation
15%
Cell Survival
14%
CD31
12%
Fibroblast
12%
Prognostic Biomarker
9%
Cell Surface
9%
Cell Proliferation
8%
Tumor Cell
8%
Cell Line
6%
Protein Family
6%
DNA Binding
6%
Multigene Family
6%
Programmed Cell Death
6%
Peptides
6%
Vascular Endothelial Cell
6%
Vascularization
6%
Peripheral Circulation
6%
CD86
5%
Synapse
5%
HLA-DR
5%
CD80
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Diseases
37%
Lymphoproliferative Disease
30%
Oxaliplatin
30%
Non Insulin Dependent Diabetes Mellitus
30%
Immunoglobulin Enhancer Binding Protein
30%
Hyperglycemia
30%
Rituximab
30%
Tumor Microenvironment
30%
Gemcitabine
30%
Gelatinase B
30%
Hemoglobin A1c
20%
Overall Survival
20%
Antiapoptotic
18%
Protein Kinase ZAP 70
16%
Chemotherapy
15%
Febrile Neutropenia
15%
Remission
15%
Protein Bcl 2
12%
Hematologic Malignancy
9%
Gliclazide
9%
NPH Insulin
9%
Biological Marker
9%
Leukemia
9%
Neoplasm
6%
Blocking Antibody
5%
Clinical Trial
5%
Natalizumab
5%
Fludarabine
5%
Integrin
5%
Fibronectin
5%
Chemokine Receptor CXCR4
5%
